针对异基因骨髓移植后并发的爱泼斯坦-巴尔病毒相关淋巴增殖性疾病的过继性免疫治疗。 - Suppr

Suppr

超能文献

Adoptive immunotherapy for Epstein-Barr virus-associated lymphoproliferative disorders complicating marrow allografts.

作者信息

O'Reilly R J, Small T N, Papadopoulos E, Lucas K, Lacerda J, Koulova L

机构信息

Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.

出版信息

Springer Semin Immunopathol. 1998;20(3-4):455-91. doi: 10.1007/BF00838055.

DOI:10.1007/BF00838055

PMID:9870257

Abstract

摘要

相似文献

Adoptive immunotherapy for Epstein-Barr virus-associated lymphoproliferative disorders complicating marrow allografts.

Springer Semin Immunopathol. 1998;20(3-4):455-91. doi: 10.1007/BF00838055.

Adoptive cell therapy with donor lymphocytes for EBV-associated lymphomas developing after allogeneic marrow transplants.

Important Adv Oncol. 1996:149-66.

Epstein-Barr virus-specific cytotoxic T-lymphocytes for adoptive immunotherapy of post-transplant lymphoproliferative disease.

Blood Rev. 2004 Sep;18(3):193-209. doi: 10.1016/j.blre.2003.12.002.

EBV specific CTL: a model for immune therapy.

Vox Sang. 1998;74 Suppl 2:497-8. doi: 10.1111/j.1423-0410.1998.tb05463.x.

Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells.

Blood. 2000 Feb 1;95(3):807-14.

Preventing Epstein-Barr virus lymphoproliferative disease after bone marrow transplantation.

J Immunother. 2001 Jul-Aug;24(4):283-4. doi: 10.1097/00002371-200107000-00002.

Establishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease.

Br J Haematol. 2014 Nov;167(3):402-10. doi: 10.1111/bjh.13051. Epub 2014 Jul 26.

Generation of EBV-specific CTLs suitable for adoptive immunotherapy of EBV-associated lymphoproliferative disease following allogeneic transplantation.

APMIS. 2002 Feb;110(2):148-57. doi: 10.1034/j.1600-0463.2002.100205.x.

An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs.

Blood. 2001 Feb 15;97(4):835-43. doi: 10.1182/blood.v97.4.835.

Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts.

Immunol Rev. 1997 Jun;157:195-216. doi: 10.1111/j.1600-065x.1997.tb00983.x.

引用本文的文献

Immunotherapeutic options for Epstein-Barr virus-associated lymphoproliferative disease following transplantation.

Immunotherapy. 2010 Sep;2(5):663-71. doi: 10.2217/imt.10.43.

Antiviral responses following L-leucyl-L-leucine methyl esther (LLME)-treated lymphocyte infusions: graft-versus-infection without graft-versus-host disease.

Biol Blood Marrow Transplant. 2009 Dec;15(12):1609-19. doi: 10.1016/j.bbmt.2009.08.020. Epub 2009 Sep 8.

Immune deficits in allogeneic hematopoietic stem cell transplant (HSCT) recipients.

Mycopathologia. 2009 Dec;168(6):271-82. doi: 10.1007/s11046-009-9181-0. Epub 2009 Jan 21.

Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease.

J Exp Med. 2004 Dec 20;200(12):1623-33. doi: 10.1084/jem.20040890.

Replicative senescence of CD8 T cells: potential effects on cancer immune surveillance and immunotherapy.

Cancer Immunol Immunother. 2004 Oct;53(10):925-33. doi: 10.1007/s00262-004-0508-x. Epub 2004 Apr 6.

Cytolytic CD4(+)-T-cell clones reactive to EBNA1 inhibit Epstein-Barr virus-induced B-cell proliferation.

J Virol. 2003 Nov;77(22):12088-104. doi: 10.1128/jvi.77.22.12088-12104.2003.

本文引用的文献

Complexity of EBV homologous DNA in continuous lymphoblastoid cell lines.

Virology. 1976 Oct 1;74(1):227-31.

DNA typing for HLA-A and HLA-B identifies disparities between patients and unrelated donors matched by HLA-A and HLA-B serology and HLA-DRB1.

Blood. 1999 Jan 1;93(1):399-409.

Epstein-Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients.

N Engl J Med. 1998 May 14;338(20):1413-21. doi: 10.1056/NEJM199805143382003.

Semiquantitative Epstein-Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation.

Blood. 1998 May 15;91(10):3654-61.

Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus In vivo.

J Exp Med. 1998 May 4;187(9):1395-402. doi: 10.1084/jem.187.9.1395.

Natural variants of the immunodominant HLA A11-restricted CTL epitope of the EBV nuclear antigen-4 are nonimmunogenic due to intracellular dissociation from MHC class I:peptide complexes.

J Immunol. 1997 Dec 1;159(11):5383-90.

Risks of developing Epstein-Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants. CAMPATH Users.

Blood. 1998 Apr 15;91(8):3079-83.

Effects of immunotherapy on experimental immunodeficiency-related lymphoproliferative disease.

Transplantation. 1998 Jan 27;65(2):264-8. doi: 10.1097/00007890-199801270-00022.

Molecular characterization of antigen-processing function in nasopharyngeal carcinoma (NPC): evidence for efficient presentation of Epstein-Barr virus cytotoxic T-cell epitopes by NPC cells.

Cancer Res. 1998 Jan 15;58(2):310-4.

Dominant cytotoxic T lymphocyte response to the immediate-early trans-activator protein, BZLF1, in persistent type A or B Epstein-Barr virus infection.

J Infect Dis. 1997 Oct;176(4):1068-72. doi: 10.1086/516513.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验